Profile of drug resistance in pulmonary tuberculosis patients in Banda Aceh and Aceh Besar
Abstract
Abstract. Increased cases of drug resistance have become a serious threat to the success of pulmonary tuberculosis (TB) elimination. The aied of this study is to determine the profile of TB patients in Banda Aceh and Aceh Besar. A total of 39 respondents with positive culture result were included in this study. The sample was TB patients who underwent treatment at the health centers and hospitals in Banda Aceh and Aceh Besar. Data collection was carried out through interviews to obtain the characteristics of respondents. Measurements of height and weight were used to determine body mass index (BMI). Observations were made to obtain the characteristics of the respondent's physical environment including the bedroom, family room, and kitchen. A culture examination and Mycobacterium tuberculosis (M.tb) sensitivity test for anti-tuberculosis drugs were done using the Mycobacteria Growth Indicator Tube (MGIT) method and the Lowenstein Jensen (LJ) method. Of the 39 samples that were tested with the M.tb sensitivity test for anti-tuberculosis drugs, 23 were confirmed to be resistant. The highest level of drug resistance was 25.6% for Isoniazid. The majority of respondents were male, 46-60 years old, high school graduates, and unemployed. There is a relationship between drug resistance and a history of previous treatment. The condition of the physical environment of patients with drug resistant TB is good. Resistance cases are higher in patients with a new case than with patients who have relapsed and have stopped using medicines.
Keywords: Tuberculosis, drug resistance, isoniazid
References
References
WHO. Global tuberculosis report 2018. Geneva; 2018.
Maulina AZ, Nur Martina Rufia. Karakteristik Penderita Tuberculosis Multidrug Resistant (TB MDR) di Sulawesi Tenggara Tahun 2014-2017. 2019;6(April):547–57.
Kementrian Kemenkes. Percepatan Eliminasi Tuberkulosis. Jakarta; 2018.
Ministry of Health RI. Indonesia health profile at 2018. 2019;
Ministry of Health of the Republic of Indonesia. Data and information: Indonesian health profile 2017. 2018;xl+184.
Dinas Kesehatan Provinsi Aceh. Data Dinkes TB Aceh 2019. Banda Aceh; 2019.
Nugrahaeni D, Malik U. Analisis penyebab resistensi obat anti tuberkulosis. J Kesehat Masy. 2015;11(1):8–15.
Munir SM, Nawas A, Soetoyo DK. Pengamatan Pasien Tuberkulosis Paru dengan Multidrug Resistant ( TB-MDR ) di Poliklinik Paru RSUP Persahabatan. J Respir Indo. 2010;30(2):92–104.
Tirtana BT. Faktor-faktor yang mempengaruhi keberhasilan pengobatan pada pasien tuberkulosis paru dengan resistensi obat tuberkulosis di wilayah Jawa Tengah. 2011.
Wang S, Ph D, Jiang G, Xia H, Zhou Y, Zhao B, et al. National survey of drug-resistant tuberculosis in China. J New Engl J Med. 2012;366(23):2161–70.
Nurhayati I, Kurniawan T, Mardiah W, Keperawatan F, Padjadjaran U. Perilaku pencegahan penularan dan faktor-faktor yang melatarbelakanginya pada pasien tuberculosis multidrugs resistance ( MDR-TB ). J Keperawatan Padjadjaran. 2015;3(3):166–75.
Pratama G. Faktor-faktor yang mempengaruhi terjadinya resistensi rifampisin dan/ isoniazid pada pasien tuberkulosis paru di BKPM Semarang. 2011.
Putri V, Yovi I, Fauzia D. Profil pasien tuberculosis multidrug resistance (TB-MDR) di Poliklinik TB-MDR RSUD Arifin Achmad Provinsi Riau periode April 2013-Juni 2014. J Online Mhs Fak Kedokt Univ Riau. 2015;1(2):1–17.
Nikmawati A, Windarwati, Hardjoeno. CLINICAL PATHOLOGY AND Majalah Patologi Klinik Indonesia dan Laboratorium Medik CLINICAL PATHOLOGY AND Majalah Patologi Klinik Indonesia dan Laboratorium Medik. Indones J Clin Pathol Med Lab. 2006;12(2):58–61.
Sinaga B. Karakteristik penderita Multidrug Resistant Tuberculosis yang mengikuti Programmatic Management of Drug-Resistant di Rumah Sakit Umum Pusat H.Adam Malik Medan. J Respir Indones. 2013;33(4):221–9.
Lisdawati V, Puspandari N, Rif L, Soekarno T, Melatiwati M, Syamsidar K, et al. Molecular epidemiology study of Mycobacterium tuberculosis and its susceptibility to anti-tuberculosis drugs in Indonesia. BMC Infect Dis [Internet]. 2015;15(366):1–8. Available from: http://dx.doi.org/10.1186/s12879-015-1101-y
Cuellar-sa A, Pasissi-crivelli A, Santana-a CA, Zenteno-cuevas R, Herna J. rrs and rpsL mutations in streptomycin-resistant isolates of Mycobacterium tuberculosis from Mexico. J Microbiol. 2013;46:30–4.
Skrahina A, Hurevich H, Zalutskaya A, Sahalchyk E. Alarming levels of drug-resistant tuberculosis in Belarus: results of a survey in Minsk. J Eur Respir. 2012;39(6):1425–31.
Pameswari P, Halim A, Yustika L. Tingkat kepatuhan penggunaan obat pada pasien tuberkulosis di Rumah Sakit Mayjen H . A . Thalib Kabupaten Kerinci. J Sains Farm dan Klin. 2016;2(2):116–21.
Napirah MR, Wandira BA, Aulia A. Factors related to the success of the treatment program of multidrug-resistant tuberculosis in polyclinic of MDR-TB of the General Hospital of Undata Palu, Indonesia. J Public Heal Indones. 2017;3(4):162–6.
Sianturi R. Analisis faktor yang berhubungan dengan kekambuhan TB paru (Studi kasus di BKPM Semarang tahun 2013). J Public Heal Unnes. 2014;3(1):1–10.
Hayashi S, Chandramohan D. Risk of active tuberculosis among people with diabetes mellitus : systematic review and meta-analysis. Trop Med Int Heal. 2018;23(10):1058–70.
Magee MJ, Kempker RR, Kipiani M, Gandhi NR, Darchia L, Tukvadze N. Diabetes mellitus is associated with cavities , smear grade , and multidrug-resistant tuberculosis in Georgia. Int J Tuber Lung Dis. 2015;19(October 2014):685–92.
Rifat M, Milton AH, Hall J, Oldmeadow C, Islam A, Husain A, et al. Development of Multidrug Resistant Tuberculosis in Bangladesh : A Case-Control Study on Risk Factors. J Plos one. 2014;9(8):2–8.
Lachmandas E, Vrieling F, Wilson LG, Joosten SA, Netea MG, Ottenhoff TH, et al. The effect of hyperglycaemia on in vitro cytokine production and macrophage infection with mycobacterium tuberculosis. PLoS One. 2015;10(2):1–13.
Widiastuti EN, Subronto YW, Promono D. Faktor risiko kejadian multi drug resistant tuberculosis di RSUP Dr. Sardjito. Ber Kedokt Masy. 2017;33(7):325.
Mohd Shariff N, Shah SA, Kamaludin F. Previous treatment, sputum-smear nonconversion, and suburban living: The risk factors of multidrug-resistant tuberculosis among Malaysians. Int J Mycobacteriology. 2016 Mar;5(1):51–8.
Chatla C, Jaju J, Achanta S, Samyuktha R, Chakramahanti S, Purad C, et al. Active case finding of rifampicin sensitive and resistant TB among household contacts of drug resistant TB patients in Andhra Pradesh and Telangana states of India – A systematic screening intervention. Indian J Tuberc. 2018;65(3):218–24.
Javaid A, Khan MA, Khan MA, Mehreen S, Basit A, Khan RA, et al. Screening outcomes of household contacts of multidrug-resistant tuberculosis patients in Peshawar, Pakistan. Asian Pac J Trop Med. 2016;9(9):909–12.
Becerra MC, Appleton SC, Franke MF, Chalco K, Arteaga F, Bayona J, et al. Tuberculosis burden in households of patients with multidrug-resistant and extensively drug-resistant tuberculosis: A retrospective cohort study. Lancet. 2011;377(9760):147–52.
Amanullah F, Ashfaq M, Khowaja S, Parekh A, Salahuddin N, Lotia-Farrukh I, et al. High tuberculosis prevalence in children exposed at home to drug-resistant tuberculosis. Int J Tuberc Lung Dis. 2014;18(5):520–7.
Ejaz M, Siddiqui AR, Rafiq Y, Malik F, Channa A, Mangi R, et al. Prevalence of multi-drug resistant tuberculosis in Karachi, Pakistan: identification of at risk groups. Trans R Soc Trop Med Hyg. 2010;104(8):511–7.
Sun Y, Harley D, Vally H, Sleigh A. Comparison of characteristics and mortality in multidrug resistant (MDR) and non-MDR tuberculosis patients in China. BMC Public Health. 2015;15(1):1–8.
Venkatesh U, Srivastava DK, Srivastava AK, Tiwari HC. Epidemiological profile of multidrug-resistant tuberculosis patients in Gorakhpur Division, Uttar Pradesh, India. J Fam Med Prim care. 2018;7(3):589–95.
Workicho A, Kassahun W, Alemseged F. Risk factors for multidrug-resistant tuberculosis among tuberculosis patients: A case-control study. Infect Drug Resist. 2017;10:91–6.
DOI: 10.24815/jks.v0i0.29643
Refbacks
- There are currently no refbacks.